News & Press - BioFlorida, Inc.

News & Press

Read about recent events, essential information and the latest community news.

Scientific Advancements
Friday, November 5, 2021 (0 Comments - view/add) Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial » Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial...
Thursday, November 4, 2021 (0 Comments - view/add) Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorizatio » Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World...
Wednesday, November 3, 2021 (0 Comments - view/add) Insightec Announces FDA Approval of Exablate Neuro for the Treatment of Parkinson’s Disease » Insightec Announces FDA Approval of Exablate Neuro for the Treatment of Parkinson’s Disease MIAMI, Nov. 3, 2021...
Friday, October 29, 2021 (0 Comments - view/add) FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of » FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age For Immed...
Thursday, October 28, 2021 (0 Comments - view/add) HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic H » HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic...
Wednesday, October 27, 2021 (0 Comments - view/add) Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infus » Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy...
Wednesday, October 20, 2021 (0 Comments - view/add) Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypopla » Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Sy...
Tuesday, October 19, 2021 (0 Comments - view/add) First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-IC » First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment...
Tuesday, October 19, 2021 (0 Comments - view/add) Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe » Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease Amb...
Thursday, October 14, 2021 (0 Comments - view/add) First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical » First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Pa...
Monday, October 11, 2021 (0 Comments - view/add) Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA f » Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, a...
Thursday, October 7, 2021 (0 Comments - view/add) Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vac » Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine License from M...
Wednesday, October 6, 2021 (0 Comments - view/add) AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intrana » AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy...
Tuesday, October 5, 2021 (0 Comments - view/add) Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Prog » Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for...
Tuesday, October 5, 2021 (0 Comments - view/add) AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US » AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US 5 October 2021 07:00 BST &n...
Monday, October 4, 2021 (0 Comments - view/add) AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Local » AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Met...
Monday, October 4, 2021 (0 Comments - view/add) Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Unio » Pfizer and BioNTech Receive CHMP Positive Opinion for COVID - 19 Vaccine Booster in the European Union...
Friday, October 1, 2021 (0 Comments - view/add) Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalizatio » Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approx...
Wednesday, September 29, 2021 (0 Comments - view/add) Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity » Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity Septemb...
Monday, September 27, 2021 (0 Comments - view/add) AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therap » AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Co...
Thursday, September 23, 2021 (0 Comments - view/add) Neurolief Announces First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation Sy » Neurolief Announces First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation System in Treating Maj...
Wednesday, September 22, 2021 (0 Comments - view/add) FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations » FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations For Immediate Release: S...
Monday, September 20, 2021 (0 Comments - view/add) Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Chil » Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years Mo...
Friday, September 17, 2021 (0 Comments - view/add) FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People » FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Cer...
Wednesday, September 15, 2021 (0 Comments - view/add) Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vacc » Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate...
Monday, September 13, 2021 (0 Comments - view/add) Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia » Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer...
Thursday, September 9, 2021 (0 Comments - view/add) Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic L » Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Pat...
Wednesday, September 8, 2021 (0 Comments - view/add) AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Po » AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion T...
Wednesday, September 8, 2021 (0 Comments - view/add) ADMA Biologics Receives FDA Approval for VanRx Aseptic Fill-Finish Machine and Related Operations » ADMA Biologics Receives FDA Approval for VanRx Aseptic Fill-Finish Machine and Related Operations Expected to Provide Im...
Thursday, September 2, 2021 (0 Comments - view/add) Omeza Receives FDA Clearance for Omeza® Collagen Matrix » Omeza Receives FDA Clearance for Omeza® Collagen Matrix First Drug Device Combination of Its Kind for Chronic W...
Thursday, September 2, 2021 (0 Comments - view/add) Inspired by the Pandemic, Emergency Physicians and Florida Firm ROBRADY design, Launch the World’s 1 » Inspired by the Pandemic, Emergency Physicians and Florida Firm ROBRADY design, Launch the World’s 1 st Ultraportable, Ul...
Wednesday, September 1, 2021 (0 Comments - view/add) Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster » Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster Septemb...
Wednesday, September 1, 2021 (0 Comments - view/add) Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluati » Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for...
Wednesday, September 1, 2021 (0 Comments - view/add) Axogen RECON(SM) Clinical Study Completes Subject Follow-up » Axogen RECON(SM) Clinical Study Completes Subject Follow-up RECON is a pivotal study supporting the Company’s Biologics L...
Monday, August 30, 2021 (0 Comments - view/add) Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and » Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants...
View "All News Items" »

Member Sign In

Forgot your password?

Don't have a profile?